A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth

BACKGROUND: Antiangiogenic therapies have been proven effective in cancer treatment. Fibroblast growth factor-2 (FGF-2) has been functionally implicated in tumour angiogenesis and is an important target of antiangiogenic therapies. The aim of this work was to develop a novel FGF-2 inhibitor for canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, D, Wei, X, Xie, K, Chen, K, Li, J, Fang, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090743/
https://www.ncbi.nlm.nih.gov/pubmed/24874473
http://dx.doi.org/10.1038/bjc.2014.282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090743/
https://www.ncbi.nlm.nih.gov/pubmed/24874473
http://dx.doi.org/10.1038/bjc.2014.282

Ejemplares similares